Arcadia Biosciences (NASDAQ:RKDA) Receives New Coverage from Analysts at StockNews.com

StockNews.com started coverage on shares of Arcadia Biosciences (NASDAQ:RKDA) in a research note released on Tuesday morning. The firm issued a sell rating on the basic materials company’s stock.

Separately, HC Wainwright reaffirmed a buy rating and set a $10.00 price target on shares of Arcadia Biosciences in a research note on Friday, April 5th.

Arcadia Biosciences Trading Up 0.8 %

Shares of RKDA opened at $2.01 on Tuesday. The firm’s fifty day simple moving average is $2.24 and its two-hundred day simple moving average is $2.67. Arcadia Biosciences has a 12 month low of $1.85 and a 12 month high of $7.30. The stock has a market capitalization of $2.73 million, a P/E ratio of -0.14 and a beta of 0.62.

Arcadia Biosciences (NASDAQ:RKDA) last announced its earnings results on Thursday, March 28th. The basic materials company reported ($2.48) EPS for the quarter, beating the consensus estimate of ($2.68) by $0.20. The company had revenue of $1.17 million for the quarter, compared to analyst estimates of $1.80 million. Arcadia Biosciences had a negative return on equity of 81.56% and a negative net margin of 246.80%. As a group, research analysts predict that Arcadia Biosciences will post -5.01 EPS for the current fiscal year.

Arcadia Biosciences Company Profile

Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.